A Phase I Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer.

Status:
Not yet recruiting

Trial end date:
2024-12-31

Target enrollment:

Participant gender:

This is a phase I, open-label, dose-escalation trial of TG6050 administered by single or repeated IV infusion(s).

Phase 1

Transgene